French drugmaker Ipsen’s Cabometyx (cabozantinib ... use in England and Wales for previously treated advanced hepatocellular carcinoma (HCC), it has been announced. Those adult patients who ...

Investors will focus on lead drug Cabometyx’s performance when Exelixis EXEL reports first-quarter 2025 results shortly. The ...

Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731] Technology appraisal guidance Cabozantinib with atezolizumab ... bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736] ...

Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular carcinoma (HCC ... and Ipsen’s Cabometyx (cabozantinib). Opdivo’s US approval for ...

We recently compiled a list of the 20 Large-Cap Stocks Insiders and Short Sellers Are Dumping Like Crazy. In this article, we ...

cabozantinib plus nivolumab, and ipilimumab plus nivolumab in non–clear cell renal cell carcinoma. A supplemental new drug application (sNDA) for the use of regorafenib (Stivarga) as a second-line ...

Systemic therapy represents the standard of care treatment for patients with advanced hepatocellular carcinoma (HCC). Given the increased risk of death from cirrhosis-related complications in patients ...